Family · Pharmaceutical analytical standards
Orforglipron
An oral GLP-1 receptor agonist that is a non-peptide small molecule: it mimics the gut hormone GLP-1 in controlling appetite and blood sugar. It was approved in the US in April 2026 for the treatment of obesity. This family brings together the active ingredient, other impurities and synthesis intermediates.
Did you know?It was discovered in Japan and licensed in 2018: unlike the GLP-1 hormone, which is a peptide, it is a small synthetic molecule and acts as a partial agonist of the receptor.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
